Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Arvinas Inc (NQ: ARVN ) 32.68 +0.57 (+1.78%) Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Arvinas Inc < Previous 1 2 3 4 5 6 Next > Analyst Ratings For Arvinas May 17, 2024 Via Benzinga Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday May 16, 2024 Via Benzinga Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) May 16, 2024 From Arvinas Inc. Via GlobeNewswire NEXTracker Posts Upbeat Earnings, Joins monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday May 15, 2024 Via Benzinga Navigating 7 Analyst Ratings For Arvinas February 28, 2024 Via Benzinga Arvinas: Q4 Earnings Insights February 27, 2024 Via Benzinga Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress May 09, 2024 From Arvinas Inc. Via GlobeNewswire ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024 May 07, 2024 ARVN stock results show that Arvinas beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update May 07, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas to Present at Upcoming Investor Conferences May 02, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High February 06, 2024 Via Investor Brand Network Forecasting The Future: 6 Analyst Projections For Arvinas February 01, 2024 Via Benzinga Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer April 24, 2024 From Arvinas Inc. Via GlobeNewswire Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options April 11, 2024 Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options. Via Investor's Business Daily Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer April 11, 2024 From Arvinas Inc. Via GlobeNewswire Expert Outlook: Arvinas Through The Eyes Of 9 Analysts December 19, 2023 Via Benzinga Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer March 18, 2024 - Awards Dr. Berkowitz an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - From Arvinas Inc. Via GlobeNewswire Arvinas to Participate in Upcoming Investor Conferences March 04, 2024 From Arvinas Inc. Via GlobeNewswire Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Via Benzinga Topics Stocks Exposures US Equities Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 01, 2024 Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. Via Benzinga Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 27, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Announces Chief Financial Officer Transition February 20, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease February 20, 2024 From Arvinas Inc. Via GlobeNewswire Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer February 14, 2024 From CARRICK THERAPEUTICS LIMITED Via GlobeNewswire SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday February 09, 2024 U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results. Via Benzinga Topics Stocks Exposures US Equities Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer February 06, 2024 From Arvinas Inc. Via GlobeNewswire Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference February 01, 2024 From Arvinas Inc. Via GlobeNewswire Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday February 01, 2024 U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Via Benzinga Topics Stocks Exposures US Equities Arvinas Appoints Jared Freedberg as General Counsel January 16, 2024 Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) From Arvinas Inc. Via GlobeNewswire Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session December 08, 2023 Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.